Messing, E. M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 341, 1781–1788 (1999).

Article  CAS  PubMed  Google Scholar 

Loblaw, D. A. et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J. Clin. Oncol. 22, 2927–2941 (2004).

Article  PubMed  Google Scholar 

Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karantanos, T. et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur. Urol. 67, 470–479 (2015).

Article  CAS  PubMed  Google Scholar 

Wong, Y. N. S., Ferraldeschi, R., Attard, G. & de Bono, J. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat. Rev. Clin. Oncol. 11, 365–376 (2014).

Article  CAS  PubMed  Google Scholar 

de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt, K. T., Huitema, A. D. R., Chau, C. H. & Figg, W. D. Resistance to second-generation androgen receptor antagonists in prostate cancer. Nat. Rev. Urol. 18, 209–226 (2021).

Article  CAS  PubMed  Google Scholar 

Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298–305 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487–495 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Labrecque, M. P. et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J. Clin. Invest. 129, 4492–4505 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Wang, Y. et al. Molecular events in neuroendocrine prostate cancer development. Nat. Rev. Urol. 18, 581–596 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Han, M. et al. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer. Cancer Cell 40, 1306–1323.e8 (2022).

Article  CAS  PubMed  Google Scholar 

Zou, M. et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 7, 736–749 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78–83 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park, J. W. et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362, 91–95 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo, H. et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat. Commun. 10, 278 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Rotinen, M. et al. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat. Med. 24, 1887–1898 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84–88 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi, J. et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18, 23–38 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dardenne, E. et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563–577 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee, J. K. et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell 29, 536–547 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bishop, J. L. et al. The master neural transcription factor BRN2 is an androgen receptor–suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54–71 (2017).

Article  CAS  PubMed  Google Scholar 

Deng, S. et al. Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat. Cancer 3, 1071–1087 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan, J. M. et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 377, 1180–1191 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li, Y. et al. SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition. Eur. Urol. 71, 68–78 (2017).

Article  CAS  PubMed  Google Scholar 

Yuan, H. et al. SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways. Cancer Cell 38, 350–365.e7 (2020).

Article  CAS  PubMed  Google Scholar 

Cyrta, J. et al. Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nat. Commun. 11, 5549 (2020).

Article